Information for Healthcare Professionals

Sign up for our newsletter to learn about important information and resources for healthcare and research professionals who serve the hereditary cancer community.

FORCE supports healthcare professionals

If you're a healthcare professional caring for individuals and families affected by hereditary cancer, FORCE has evidence-informed tools, education and support resources to facilitate shared decision-making, and compassionate, informed care to help.

Help Your Patients Find Support

FORCE support programs include virtual community meetings, trained guidance from peer navigators and community message boards. We offer your patients multiple ways to connect with others in a safe, supportive environment. Download our flier with all our support programs.

Support Meetings & Events

FORCE's Support Meetings and Events Calendar provides details on upcoming support meetings, webinars and partner events. 

View Calendar

1 to 1 Support & Navigation

FORCE's Peer Navigation Program connects those seeking support with a trained peer navigator who shares a similar experience.  

Learn More

Spotlight

ABFM Performance Improvement Module  ›

This module is open to board-certified family medicine doctors. Click on the title or log in to your MyABFM Portal and search for "Improving Assessment and Management of Hereditary Breast and Gynecologic Cancer."

Looking for the latest guidelines?

FORCE provides gene-specific summaries on cancer risk, screening, prevention and treatment guidelines, and resources for individuals with inherited cancer risk. 

Customizable Resources

Add your logo and contact info to FORCE materials

FORCE’s resource center allows you to personalize FORCE publications and genetic test result disclosure letters with your contact information and logo for printing or sharing on demand. We also provide links and QR codes to curated content for specific genes, which you can use within your own materials.

Learn More

Insurance Coverage & Appeals

Find information on insurance coverage and reimbursement for health insurance appeals. Our customizable insurance appeal letters are designed to help you and your patients quickly appeal insurance denials.

Learn More

Find Research Studies Enrolling People with Inherited Mutations

Use our search and enroll tool to connect your patients to the latest cancer prevention, treatment and quality-of-life studies enrolling people with or at high risk for hereditary cancers. 

Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)

This study is testing whether a type of blood test called a liquid biopsy can find very small amounts of cancer left in the body after treatment—before cancer shows up on scans or causes symptoms.The...

ADHERE: Survey about Pancreatic Cancer Screening Options for People with Inherited Risk

The purpose of this study is to understand knowledge and opinions about pancreatic cancer screening, access to and decision-making around screening, and how a blood-based test might influence screening among individuals with inherited (germline) mutations...

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

This trial will study the safety, tolerability, and initial effectiveness of MOMA-341, a new type of targeted therapy, alone or in combination with a standard chemotherapy (irinotecan) or together with an immunotherapy to treat people...

Go Behind the Headlines

Force's XRAY program shares easy-to-understand information on the latest cancer research.

Guideline : FDA recommends testing to prevent serious side effects from 5-FU and capecitabine chemotherapy

A small number of people treated with the chemotherapy drugs 5-FU (5-fluorouracil) or capecitabine (Xeloda) can have serious or even life-threatening side effects because their body breaks down the drug more slowly than is typical....

Topic : What patients need to know about liquid biopsies in cancer care

Liquid biopsies are tests that look for signs of cancer in blood or other body fluids. These signs can include cancer cells that have broken away from a tumor, pieces of cancer cell DNA and...

Study : Treating triple-negative breast cancer in people with inherited BRCA1 or BRCA2 mutations

This review summarizes two studies highlighted during the 2025 San Antonio Breast Cancer Symposium. Both studies focus on targeted therapy and immunotherapy given before surgery to treat early-stage triple-negative breast cancer in people with inherited...

Quickly share FORCE resources with just a few clicks!

FORCE’s Healthcare Provider Toolkit makes it easy to distribute resources across your favorite social media platforms.